<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The protein kinase BRAF is a key component of the <z:mp ids='MP_0011356'>RAS</z:mp>-RAF signaling pathway which plays an important role in regulating cell proliferation, differentiation, and survival </plain></SENT>
<SENT sid="1" pm="."><plain>Mutations in BRAF at codon 600 promote catalytic activity and are associated with 8% of <z:hpo ids='HP_0000001'>all</z:hpo> human (solid) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, including 8% to 10% of <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we report the preclinical characterization of vemurafenib (RG7204; PLX4032; RO5185426), a first-in-class, specific small molecule inhibitor of BRAF(V600E) in BRAF-mutated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>As a single agent, vemurafenib shows dose-dependent inhibition of ERK and MEK phosphorylation, thereby arresting cell proliferation in BRAF(V600)-expressing cell lines and inhibiting <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in BRAF(V600E) bearing <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Because vemurafenib has shown limited single-agent clinical activity in BRAF(V600E)-mutant metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, we therefore explored a range of combination therapies, with both standard agents and targeted inhibitors in preclinical <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>In a BRAF-mutant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e> with de novo resistance to vemurafenib (RKO), <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> inhibition by vemurafenib was enhanced by combining with an AKT inhibitor (MK-2206) </plain></SENT>
<SENT sid="6" pm="."><plain>The addition of vemurafenib to <z:chebi fb="0" ids="31348">capecitabine</z:chebi> and/or bevacizumab, cetuximab and/or irinotecan, or <z:chebi fb="0" ids="114785">erlotinib</z:chebi> resulted in increased antitumor activity and improved survival in <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Together, our findings suggest that the administration of vemurafenib in combination with standard-of-care or novel targeted therapies may lead to enhanced and sustained clinical antitumor efficacy in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> harboring the BRAF(V600E) mutation </plain></SENT>
</text></document>